Radiotherapy for Extramedullary Plasmacytoma of the Head and Neck
- Graduate Medical Education-Translational Year Program, Saint John's Mercy Medical Center, St. Louis, MO (Canada)
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN (United States)
- Division of Hematology, Mayo Clinic, Rochester, MN (United States)
Purpose: To define the effectiveness of radiotherapy in the treatment of patients with extramedullary plasmacytoma of the head and neck (EMPHN). Methods and Materials: We searched the Mayo Clinic Rochester Department of Radiation Oncology electronic Tumor Registry and identified 18 consecutive patients with a diagnosis of solitary EMPHN. Sixteen patients were treated with radiotherapy at initial diagnosis and 2 received salvage radiotherapy for local failure after surgery. Median dose administered was 50.4 Gy. Median follow-up was 6.8 years. Results: One patient (6%) developed a marginal recurrence 12 months after treatment. Six patients (33%) developed multiple myeloma (2 patients) or plasmacytomas at distant sites (4 patients) at a median of 3.1 years after diagnosis (range, 0.02 to 9.6 years). Median and 5- and 10-year overall survival rates from the date of diagnosis are 12.5 years, 88%, and 55%, respectively. Two patients (11%) developed a radiation-induced malignancy at 6.5 and 6.9 years after treatment. Conclusions: Radiotherapy provides excellent local and regional tumor control and survival in patients with EMPHN. To the best of our knowledge, this is the first report of presumed radiation-induced malignancy in this patient population.
- OSTI ID:
- 21172630
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 73, Issue 3; Other Information: DOI: 10.1016/j.ijrobp.2008.04.077; PII: S0360-3016(08)00825-0; Copyright (c) 2009 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Outcomes and patterns of failure in solitary plasmacytoma: A multicenter Rare Cancer Network study of 258 patients
Radiotherapy for solitary extramedullary plasmacytoma in the head-and-neck region: A dose greater than 45 gy to the target volume improves the local control